Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report report published on Monday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of ENZ opened at $1.13 on Monday. The business has a fifty day moving average of $1.12 and a 200 day moving average of $1.12. Enzo Biochem has a 52-week low of $0.99 and a 52-week high of $1.50.

Institutional Trading of Enzo Biochem

A hedge fund recently raised its stake in Enzo Biochem stock. Renaissance Technologies LLC grew its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 2.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,499,546 shares of the medical research company’s stock after purchasing an additional 64,417 shares during the quarter. Renaissance Technologies LLC owned approximately 4.86% of Enzo Biochem worth $2,725,000 at the end of the most recent quarter. Institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.